ClinicalTrials.gg
CompletedNCT02254577Updated Aug 2, 2018

Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer

A Phase 4 interventional study of Endometrin® plus Progesterone in Oil (PIO) and Progesterone in Oil (PIO) Only in Infertility, sponsored by Shady Grove Fertility Reproductive Science Center. Completed at 14 sites in United States. Open to female participants aged 18 Years to 48 Years. Per ClinicalTrials.gov, last updated 2018-08-02.

Sponsored by Shady Grove Fertility Reproductive Science Center · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,139
Allocation
Randomized
Ages
18 Years to 48 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.

Enrollment
10th of 274
1,139 · median 84
Started
2014
with 12 others
Phase 4
35 of 395
3 open now
Registered
197th of 395
by date

Among the 395 studies in Infertility with a site in United States, this one is the 10th largest by enrollment of the 274 interventional ones that give a count, is one of 13 that started in 2014, is one of 35 in phase 4, and was the 197th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 48 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Infertility with a site in United States, or all of them as a file.
02

Study summary

To determine whether the of vaginal progesterone replacement for frozen embryo transfer results in equivalent live birth rates to intramuscular injection progesterone replacement.

Read the detailed description

The purpose of this ongoing study is to look at whether Endometrin® (vaginal micronized progesterone tablets) supplemented by intramuscular injection of progesterone in oil (PIO) work as well as PIO alone for women undergoing transfer of frozen-thawed blastocyst(s). Another goal of the study is to determine whether patients prefer Endometrin or PIO. Endometrin® has been approved by the United States Food and Drug Administration, or FDA, "to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women." (FDA New Drug Approval Letter, Endometrin®, 2007). The use of Endometrin® (vaginal micronized progesterone tablets) in this study is investigational. An investigational use is one that is not approved by the U.S. Food and Drug Administration (FDA).

Approximately 1170 women between the ages of 18-48 who are having difficulty becoming pregnant and wish to undergo frozen embryo transfer will be asked to participate. The participants will be recruited from among patients of Shady Grove Fertility.

One-half of the participants who qualify and wish to take part in the ongoing study will be randomized (assigned by chance, like the flip of a coin) to receive Endometrin® and an intramuscular injection of PIO every third day. One-half will be randomized to receive an intramuscular injection of PIO every day. This study is a type of study called an "open label," assessor-blind study. This means that you and your doctor will know which treatment you are assigned and receive; however, the person analyzing the information obtained from the study will not know which patients received which study treatments.

Patients enrolling in the study will receive the medications for their frozen embryo transfer cycle free of charge.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Infertility
  • Progesterone
  • ART
  • IVF
  • FET
  • FBT
  • Frozen Embryo Transfer
04

Who can participate

Ages eligible
18 Years to 48 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Female age between 18 and 48 years
  3. Having available blastocyst(s) frozen by vitrification method at our center (Shady Grove Fertility).
  4. Standard eligibility criteria to undergo frozen blastocyst transfer at Shady Grove Fertility.

Exclusion criteria

Exclusion Criteria:

  1. Requires fresh embryos or surrogate carrier
  2. Embryos from frozen oocytes and embryos frozen more than once
  3. Any embryo cryopreserved by slow freeze method and/or prior to blastocyst stage
  4. Presence of any systemic disease for ART
  5. History of more than 3 failed cycles in previous ART attempts and/or more than 3 recurrent pregnancy losses after ET
  6. Surgical or medical condition or requirement for medication, which may interfere with absorption, distribution, metabolism, or excretion of the drugs to be used
  7. Subjects with a (BMI) of \<18 or >38 kg/m2 at screening
  8. Current or recent substance abuse, including alcohol and tobacco. (Note: Subjects who stopped tobacco usage at least 3 months prior to screening visit will be allowed)
  9. Currently breast feeding, pregnant, or having (a) contraindication(s) to pregnancy
  10. Refusal or inability to comply with the requirements of the protocol for any reason, including scheduled clinic visits and laboratory tests
  11. Trophectoderm or blastomere of the blastocyst(s) to be transferred.
  12. Documented intolerance or allergy to any of the medications used, including the study medication
  13. Participation in any experimental drug study within 60 days prior to screening
  14. If a subject undergoes more than two frozen blastocyst transfers meeting study criteria, she will only be eligible to enroll in the study for two of these.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,139 participants (actual)

Study arms

  • Experimental
    Endometrin® plus Progesterone in Oil (PIO)

    Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the Endometrin® plus PIO arm will take progesterone as 2 100mg tablets of Endometrin® inserted vaginally twice daily. In addition, on the first day of Endometrin® therapy, patients randomized to this arm will take a 50mg intramuscular injection (1mL) of PIO and will repeat this injection every third day. Patients in this arm will undergo Frozen Embryo Transfer on the fifth day of Endometrin® therapy.

    Drug: Endometrin® plus Progesterone in Oil (PIO)

  • Active comparator
    Progesterone in Oil (PIO) Alone

    Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the PIO Only arm will take progesterone as a daily 50mg intramuscular injection (1mL) of PIO and will undergo Frozen Embryo Transfer on the sixth day of taking this medication.

    Drug: Progesterone in Oil (PIO) Only

Interventions

  • DrugEndometrin® plus Progesterone in Oil (PIO)

    Also known as: Vaginal Micronized Progesterone Tablet, Progesterone in Sesame Oil Injection

  • DrugProgesterone in Oil (PIO) Only

    Also known as: Progesterone in Sesame Oil Injection

06

What researchers measure

Primary outcomes

  1. Live Birth

    Live born infant at 23 weeks' estimated gestational age or greater.

    Time frame: ~40 weeks post Frozen Embryo Transfer

Secondary outcomes

  1. Ongoing Implantation Rate

    maximum # fetal heartbeats divided by total number of embryos transferred

    Time frame: 7-8 weeks after embryo transfer

  2. Implantation rate

    Maximum number of gestational sacs, divided by total number of embryos transferred

    Time frame: 5-6 weeks post embryo transfer

  3. Biochemical pregnancy

    detection of beta hCG (pregnancy hormone) above 5 IU/L

    Time frame: ~10 days following embryo transfer

  4. Clinical pregnancy

    Presence of gestational sac(s) at 5-6 weeks post ET

    Time frame: 5-6 weeks following embryo transfer

  5. Serum progesterone level

    blood draw

    Time frame: ~10 days following embryo transfer

  6. Patient satisfaction with Endometrin® vs. intramuscular progesterone in oil

    As assessed by brief, optional online survey

    Time frame: between 0 and 10 days following embryo transfer

07

Study locations

14 sites
  • Shady Grove Fertility Center
    Washington, District of Columbia 20006, United States
  • Shady Grove Fertility Center
    Washington, District of Columbia 20016, United States
  • Shady Grove Fertility Center
    Annapolis, Maryland 21401, United States
  • Shady Grove Fertility Center
    Baltimore, Maryland 21202, United States
  • Shady Grove Fertility Center
    Bel Air, Maryland 21015, United States
  • Shady Grove Fertility Center
    Columbia, Maryland 21044, United States
  • Shady Grove Fertility Center
    Frederick, Maryland 21702, United States
  • Shady Grove Fertility Center
    Rockville, Maryland 20850, United States
  • Shady Grove Fertility Center
    Towson, Maryland 21204, United States
  • Shady Grove Fertility
    Camp Hill, Pennsylvania 17011, United States
  • Shady Grove Fertility Center
    Chesterbrook, Pennsylvania 19087, United States
  • Shady Grove Fertility Center
    Annandale, Virginia 22003, United States
  • Shady Grove Fertility Center
    Leesburg, Virginia 20176, United States
  • Shady Grove Fertility Center
    Woodbridge, Virginia 22192, United States
08

References and documents

Publications

  • Shapiro DB, Pappadakis JA, Ellsworth NM, Hait HI, Nagy ZP. Progesterone replacement with vaginal gel versus i.m. injection: cycle and pregnancy outcomes in IVF patients receiving vitrified blastocysts. Hum Reprod. 2014 Aug;29(8):1706-11. doi: 10.1093/humrep/deu121. Epub 2014 May 20. PubMed 24847018 ↗
  • Feinberg EC, Beltsos AN, Nicolaou E, Marut EL, Uhler ML. Endometrin as luteal phase support in assisted reproduction. Fertil Steril. 2013 Jan;99(1):174-178.e1. doi: 10.1016/j.fertnstert.2012.09.019. Epub 2012 Nov 6. PubMed 23137759 ↗
  • Paulson RJ, Collins MG, Yankov VI. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J Clin Endocrinol Metab. 2014 Nov;99(11):4241-9. doi: 10.1210/jc.2013-3937. Epub 2014 Feb 25. PubMed 24606090 ↗
  • Devine K, Richter KS, Jahandideh S, Widra EA, McKeeby JL. Intramuscular progesterone optimizes live birth from programmed frozen embryo transfer: a randomized clinical trial. Fertil Steril. 2021 Sep;116(3):633-643. doi: 10.1016/j.fertnstert.2021.04.013. Epub 2021 May 13. PubMed 33992421 ↗
  • Devine K, Richter KS, Widra EA, McKeeby JL. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018 Feb;109(2):266-275. doi: 10.1016/j.fertnstert.2017.11.004. Epub 2018 Jan 17. PubMed 29338855 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Apr 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2014
First posted
Oct 2, 2014
Start
Oct 2014
Primary completionActual
Apr 27, 2018
CompletionActual
Apr 27, 2018
Last update
Aug 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02254577
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Responsible party
Sponsor
First posted
Oct 2, 2014
Start date
Oct 2014
Primary completion
Apr 27, 2018
Completion
Apr 27, 2018
Last update
Aug 2, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion